title: Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor.
abstract: A 47-year-old woman with branch retinal arterial occlusion treated with sodium ozagrel is described. The patient presented with acute visual field loss in her right eye. Blood tests demonstrated the elevation of beta-thromboglobulin and platelet factor 4. Sodium ozagrel, a thromboxane A2 synthetase inhibitor, 160 mg daily was administered for 14 days. This treatment prevented exacerbation of retinal arterial thrombosis and produced a marked improvement in the visual field loss. Sodium ozagrel may be a useful drug in the treatment of acute retinal arterial occlusion thought to be caused by thrombosis.
authors.affiliation: Department of Internal Medicine, Saga Medical School, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Emura
authors.forename: N
authors.initials: N
authors.lastname: Takeuchi
authors.forename: M
authors.initials: M
authors.lastname: Enoki
authors.forename: K
authors.initials: K
authors.lastname: Oogushi
authors.forename: T
authors.initials: T
authors.lastname: Takashima
authors.forename: K
authors.initials: K
authors.lastname: Ohmori
authors.forename: I
authors.initials: I
authors.lastname: Saito
mesh_terms: D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008689:Methacrylates / Q000627:therapeutic use*; D008875:Middle Aged; D015356:Retinal Artery Occlusion / Q000188:drug therapy*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014794:Visual Fields / Q000187:drug effects
chemical_list: D004791:Enzyme Inhibitors; D008689:Methacrylates; D013930:Thromboxane-A Synthase; C034364:ozagrel